ArticleKidney international reports2021
Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study of Safety and Tolerance.
Article in Kidney international reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review.Expert review of anti-infective therapy · 2022Pooled it
- Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review.Frontiers in medicine · 2021Pooled it
- The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load.Scientific reports · 2025Article
- SARS-CoV-2 viral load is linked to remdesivir efficacy in severe Covid-19 admitted to intensive care.Scientific reports · 2024Article
- Efficacy and Safety of Remdesivir in Adult Solid Organ Transplant Recipients: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Association of renal function with mortality among hospitalized patients treated with remdesivir for COVID-19.PloS one · 2024Observational
- Remdesivir: A Review in COVID-19.Drugs · 2023Review
- Paxlovid for hospitalized COVID-19 patients with chronic kidney disease.Antiviral research · 2023Article
- Review
- Sotrovimab in SARS-COV-2 chronic hemodialysis patients in the Omicron era. Is intradialytic administration feasible? Report of 4 cases.Journal of nephrology · 2023Article
- COVID-19-related liver injury: Focus on genetic and drug-induced perspectives.World journal of virology · 2023Article
- [Treatment of patients with COVID-19 on Hemodialysis: Efficacy of Remdesivir].Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia · 2022Article
- Remdesivir use in COVID-19 patients with end-stage kidney disease on intermittent hemodialysis: An absolute contraindication?Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2022Article
- Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients.Antimicrobial agents and chemotherapy · 2022Observational
- Pharmacologic Treatment and Management of Coronavirus Disease 2019.Infectious disease clinics of North America · 2022Review
- Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2022Review
- COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment.Kidney international · 2022Review
- Safety and Tolerability of Remdesivir in Patients with End-stage Renal Disease on Maintenance Hemodialysis.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2022Article
- A Propensity Score-Matched Observational Study of Remdesivir in Patients with COVID-19 and Severe Kidney Disease.Kidney360 · 2022Observational
- Efficacy and Safety of Remdesivir in COVID-19 Positive Dialysis Patients.Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are scarce data regarding the use of remdesivir in patients with severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) and end-stage renal disease as US Food and Drug Administration cautions against its use in patients with an estimated glomerular filtration rate <30 ml/min/1.73m
methodsWe conducted an observational prospective study in 48 dialysis-dependent patients with SARS-CoV-2 infection who received remdesivir as part of institutional treatment protocol. During the treatment period, 100 mg of remdesivir was given 4 hours before hemodialysis sessions. Liver function tests, inflammatory markers such as serum C-reactive protein, serum ferritin and lactate dehydrogenase levels, and oxygen requirement before and after remdesivir treatment were compared.
resultsThere were no events of significant liver function test alterations with the administration of 2 to 6 doses of remdesivir. A significant decline in serum C-reactive protein level (
conclusionRemdesivir was well tolerated and found safe in our study. If initiated within 48 hours of hospitalization, it reduces recovery time. Assessing the mortality benefits of remdesivir in these patients requires a randomized controlled trial with a larger population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.